📰 Registration Document News
Page 54 - Registration Document News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Registration Document. Real-time updates on events, politics, business and more.
May 10, 2023
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for
May 10, 2023
Euronext Tech Leaders - DSS mid-caps www.neurones.net Press Relations:OConnectionValérie HackenheimerTel.: +33 6 12 80 35 20vhackenheimer@oconnection.frNEURONESMatthieu VautierTel.: +33 1 41... | May 10, 2023
May 10, 2023
PROPOSED RESOLUTIONS 2023 GENERAL MEETING Proposed resolutions and explanatory statements ... | May 10, 2023
May 10, 2023
Paris, France, Wednesday May 10, 2023, 6:00 pm CEST - GenSight Biologics , a biopharma company focused on developing and commercializing innovative gene therapies for retinal... | May 10, 2023
May 10, 2023
GOTHENBURG, SWEDEN / ACCESSWIRE / May 10, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 10, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and
May 10, 2023
Paris, May 10, 2023 - 5.45 pm Financial information for the 1st quarter of 2023 - NRJ Group Consolidated revenue for the first quarter of... | May 10, 2023
May 10, 2023
PRESS INFORMATIONHeading: 1st quarter 2023 revenue        Nanterre, May 10, 2023 (after trading) Organic growth up 15.1% in 1st quarter 2023 (in millions...
May 9, 2023
ERYTECH Provides Business and Financial Update for the First Quarter of 2023 Combination with Pherecydes, intending to create a global leader in extended phage therapies to target antimicrobial
May 9, 2023
Lille ; Cambridge ; Zurich ; May 9, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is... | May 9, 2023
May 5, 2023
Press ReleaseVELIZY-VILLACOUBLAY, France — May 5, 2023 COMBINED GENERAL SHAREHOLDERS’ MEETING OF MAY 24, 2023 Availability of preliminary documents ...